Q1 Earnings Forecast for Adicet Bio Issued By HC Wainwright

Adicet Bio, Inc. (NASDAQ:ACET - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Adicet Bio in a research report issued to clients and investors on Wednesday, July 23rd. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.28) for the quarter. HC Wainwright currently has a "Buy" rating and a $4.00 target price on the stock. The consensus estimate for Adicet Bio's current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Adicet Bio's Q2 2026 earnings at ($0.29) EPS.

Adicet Bio (NASDAQ:ACET - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.03.

Separately, Wall Street Zen assumed coverage on Adicet Bio in a report on Friday, May 16th. They set a "hold" rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $6.00.

Adicet Bio Trading Down 0.5%

Shares of NASDAQ:ACET traded down $0.00 during midday trading on Thursday, hitting $0.77. The company had a trading volume of 122,175 shares, compared to its average volume of 380,294. Adicet Bio has a 12 month low of $0.45 and a 12 month high of $1.70. The stock has a market cap of $63.81 million, a price-to-earnings ratio of -0.59 and a beta of 1.62. The firm has a fifty day simple moving average of $0.71 and a 200 day simple moving average of $0.76.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACET. Virtu Financial LLC bought a new stake in shares of Adicet Bio in the fourth quarter valued at about $29,000. Wealthedge Investment Advisors LLC bought a new stake in shares of Adicet Bio in the fourth quarter valued at about $71,000. Vontobel Holding Ltd. lifted its holdings in shares of Adicet Bio by 33.3% in the second quarter. Vontobel Holding Ltd. now owns 80,000 shares of the company's stock valued at $49,000 after purchasing an additional 20,000 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Adicet Bio by 25.1% in the fourth quarter. Northern Trust Corp now owns 140,369 shares of the company's stock valued at $135,000 after purchasing an additional 28,153 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Adicet Bio by 87.3% in the fourth quarter. JPMorgan Chase & Co. now owns 150,485 shares of the company's stock valued at $145,000 after acquiring an additional 70,132 shares during the last quarter. 83.89% of the stock is currently owned by institutional investors.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.